FTSE MIB
33.765,27 -505,85 (-1,48%) Dow Jones
37.797,50 -663,42 (-1,72%) Nasdaq
15.458,45 -254,29 (-1,62%) Nikkei 225
37.628,48 -831,60 (-2,16%) Petrolio
82,46 -0,35 (-0,42%) Bitcoin EUR
59.436,23 -2.380,39 (-3,85%)
Ascendis Pharma A/S (ASND)
| Chiusura precedente | 143,18 |
| Aperto | 140,01 |
| Denaro | 137,75 x 100 |
| Lettera | 139,60 x 100 |
| Min-Max giorno | 137,74 - 140,01 |
| Intervallo di 52 settimane | 66,03 - 161,00 |
| Volume | |
| Media Volume | 352.483 |
| Capitalizzazione | 7,872B |
| Beta (5 anni mensile) | 0,51 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -9,11 |
| Prossima data utili | 25 apr 2024 - 29 apr 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 0,29 |
GlobeNewswireAscendis Presents TransCon™ PTH Data at the American Thyroid Association Annual Meeting
– At Week 26, 81% of patients in Phase 3 PaTHway Trial with chronic post-surgical hypoparathyroidism, the most common cause of this disease, achieved independence from conventional therapy while maintaining normocalcemia following treatment with TransCon PTH – Post-surgical patients treated with TransCon PTH self-reported significant improvements in disease-related symptoms, physical functioning, and daily life compared to those on placebo – Results for post-surgical patients (n=70) comparable t
- GlobeNewswire
Ascendis Pharma Presents Results from Long-Term enliGHten Trial of TransCon™ hGH in Pediatric Growth Hormone Deficiency
- The majority of children and adolescents treated once weekly with TransCon hGH (lonapegsomatropin) met or exceeded average parental height SDS at time of treatment completion or last visit - Trial demonstrated the long-term safety of TransCon hGH in patients treated up to 6 years COPENHAGEN, Denmark, Sept. 23, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced results from enliGHten, the Company’s open-label extension trial evaluating the long-term safety and efficacy
- GlobeNewswire
Ascendis Pharma Launches SKYTROFA® (lonapegsomatropin) in Germany for the Once-Weekly Treatment of Children and Adolescents with Growth Hormone Deficiency
COPENHAGEN, Denmark, Sept. 15, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the launch in Germany of SKYTROFA® (lonapegsomatropin), its growth hormone approved in the European Union for the once-weekly treatment of children and adolescents ages 3 to 18 years with growth failure due to insufficient endogenous growth hormone secretion (growth hormone deficiency, or GHD). “SKYTROFA is designed to deliver unmodified somatropin, the same growth hormone used in daily ped
